Introduction
Myeloproliferative neoplasm (MPN), including polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) are rare disorders with an annual incidence rate of 2.1 per 100.000 person-years. 1 The course of MPN is complicated mainly by vascular events and transformation to myelofibrosis or leukemia; secondary malignancies may occur with a low incidence. 2 A previous study demonstrated that patients with MPN have a 3.44-fold higher risk of developing lymphoid neoplasm (LPN) than the general population. 3 On this basis, a common genetic susceptibility may be taken into account. In familial-MPN setting, first-degree relatives of patients with MPN have a 5-to 7-fold higher risk of developing MPN, 4 and an increased risk of secondary malignancies. 5 Likewise, first-degree relatives of patients with chronic lymphocytic leukemia or lymphoplasmocytic lymphoma are at increased risk for LPN. 6, 7 Inherited genetic factors with a role in the development of sporadic MPN have been recently defined. [8] [9] [10] More than 80% of JAK2 (V617F) mutations are acquired on a particular JAK2 gene haplotype, the GGCC or 46/1 haplotype. This sequence variant of the JAK2 gene confers susceptibility to JAK2-mutated MPN [8] [9] [10] and to JAK2-wild type MPN.
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To define the association of MPN and LPN, we explored our MPN database to find out those patients having a well defined diagnosis of LPN. In addition, we investigated whether GGCC JAK2 haplotype and familial clustering are overrepresented in LPN-MPN patients.
Design and Methods

Study population
This study includes 1,915 consecutive patients with PV, ET, PMF, post-ET and post-PV MF recorded in our MPN database. Patients with diagnosis of MPN not otherwise specified were excluded from the study. All patients were followed at the Division of Hematology, 
Analysis of VH gene usage and mutations
The analysis of immunoglobulin heavy chain gene variable, diversity and joining (IGHV-D-J) genes was performed on mononuclear cells obtained from peripheral blood or bone marrow samples after isolation on Ficoll gradient, as previously described. 21 We studied eight of 10 patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and chronic lymphoproliferative disorder of B lineage (B-LPL), of whom DNA was available, in order to evaluate whether CLL/SLL/B-LPL associated to MPN display a particular repertoire of IGHV genes.
Statistical analysis
To tackle the aim of the study, only LPN occurring after the diagnosis of MPN were considered. The period at risk was defined for each patient from the date at diagnosis of MPN to the date of occurrence of LPN, date of death, or date of the last follow-up, whichever came first. The relative risk of LPN was expressed as a standardized incidence ratio (SIR), defined as the ratio between observed and expected cases. The expected number of LPN cases was estimated using sex and age incidence rates reported by To look for clinical arguments in favour of an inherited susceptibility to haematological neoplasia we focused on the 1,050 MPN patients interviewed about familial history.
We ET (12 cases), whose survival is generally longer due to the good prognosis of ET. 2 Conversely, the lowest number of LPN was observed in patients with PMF (n=2), whose life expectancy is not enough long-lasting to develop secondary lymphoid neoplasms.
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In conclusion, patients with MPN have a higher risk of developing LPN than the general population. No difference in term of familial clustering was observed between LPN-MPN and MPN. We did not find a statistical association between the JAK2 GGCC haplotype and LPN-MPN. These results are based on a low umber of patients with both MPN and LPN, due to the rare occurrence of both disorders. Moreover familial history and JAK2 haplotype were available only in a subgroup of patients. Further studies considering larger patients cohorts extensively interviewed for familial history and genotyped for JAK2 haplotype are needed to definitively rule out an association.
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